Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Hormone Therapy Risk Management Options Include Narrower Indication

Executive Summary

FDA is considering limiting hormone therapy indications to patients with more severe menopausal symptoms or those at a high risk for osteoporosis, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Oct. 24
Advertisement

Related Content

Berlex Climara Pro Triglyceride Effect Is Point Of Difference For HRT Patch
HRT Class Labeling Should Not Cover Topical Estrogens, Pharmacia Says
Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.
King Altace Scripts Shift To 10 Mg; Dosage From HOPE Trial Helps Fuel Growth
FDA Women’s Health Initiative Advisory Committee Meeting Postponed
Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half
Prempro, Premarin Not Indicated For Coronary Heart Disease – Revised Label
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Advertisement
UsernamePublicRestriction

Register

PS040684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel